NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

NEW YORK – In March, a new EU-funded project will commence that aims to deliver a series of new tests and tools for diagnosing urinary tract infections in low- and medium-income countries, especially ...

NEW YORK – The US Department of Justice announced this week the resolution of two separate laboratory fraud cases, one in which a North Carolina lab allegedly billed Medicaid for unnecessary urine ...